Shionogi & Co., Ltd.
Notice Regarding the Acquisition of IntraBio, Inc. as a Wholly Owned Subsidiary in the United States
A U.S. group company will acquire IntraBio to expand global deployment of AQNEURSA and strengthen its rare disease portfolio. The purchase price is 2,000 million USD, with completion expected between November and December 2026. All shares of IntraBio will be acquired, and global rights to AQNEURSA will be obtained.
Key Figures
- Acquisition consideration: 2,000 million USD
- Acquisition of global exclusive rights to AQNEURSA and related compounds
- Expected transaction execution period: November 2026–December 2026 (expected)
AI要約
Overview and Background of the Transaction
Shionogi & Co., Ltd. has entered into an agreement for its U.S. group company, Shionogi Inc., to acquire IntraBio, Inc. The acquisition secures global rights to AQNEURSA and strengthens expertise in the rare disease field. By incorporating IntraBio’s rare disease know-how, the company aims to accelerate development programs for fragile X syndrome, Jordan syndrome, Pompe disease, and other programs.
Financial and Business Impact and Outlook
The acquisition consideration is 2,000 million USD. Completion is anticipated between November and December 2026. AQNEURSA’s label expansion for NPC and A-T is in progress, and the company plans to leverage the RADICAVA rare disease business foundation to expand supply of AQNEURSA. The impact on future consolidated results is under review; any matters requiring disclosure will be announced promptly.
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
